Abstract：OBJECTIVE: To evaluate factors for predicting ventricular arrhythmia, the clinical effect of drugs on patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), and their long-term outcomes. METHODS: Six patients diagnosed with CPVT underwent a series of electrocardiograms and 24-hour Holter monitoring. β-blockers were recommended for all patients, while some patients were also prescribed propafenone and 1 patient underwent catheter-based renal sympathetic denervation (RDN). The characteristics of electrocardiogram, arrhythmia and long-term outcomes were monitored. RESULTS: Syncope episodes did not occur any longer in 1 patient on β-blocker, but recurred in 3 other patients and 2 patients died (one due to his cessation of metoprolol for 3 months). Inverted and/or bifid T waves and abnormal U wave were observed in the precordial leads. T wave alternans was observed in 4 patients in the precordial leads. These abnormal electrocardiogram features disappeared or diminished with β-blocker treatment. All spontaneous episodes of ventricular tachycardia occurred prior to sinus tachycardia and frequent polymorphic premature ventricular contractions. CONCLUSIONS: Bifid and/or inverted T waves, T wave alternans and abnormal U waves together with sinus tachycardia and frequent premature ventricular contractions are indicator for predicting ventricular arrhythmia and assessing the effect of β-blockers. Compliance with β-blocker treatment is a strong indicator of outcome.
YU Sheng-Yong,SHEN Jian-Hua,LU Jing-Ping et al. Long-term outcomes and factors for predicting ventricular arrhythmia in patients with catecholaminergic polymorphic ventricular tachycardia[J]. CJCP, 2013, 15(8): 671-677.
Liu N, Ruan Y, Priori SG. Catecholaminergic polymorphic ventricular tachycardia [J]. Prog Cardiovasc Dis, 2008, 51(1): 23-30.
[2]
Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, Kainulainen K, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts [J]. J Am Coll Cardiol, 1999, 34(7): 2035-2042.
[3]
Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia [J]. Circulation, 2009, 119(18): 2426-2434.
[4]
Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation [J]. J Cardiovasc Electrophysiol, 2008, 19(12): 1319-1321.
[5]
Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia [J]. Heart Rhythm, 2006, 3(12): 1486-1489.
Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia [J]. Heart Rhythm, 2011, 8(6): 864-871.
[8]
Bruce RA, Blackmon JR, Jones JW, Strait G. Exercising testing in adult-normal subjects and cardiac patients [J]. Pediatrics, 1963, 32: SUPPL 742-756.
[9]
Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome [J].Mayo Clin Proc, 2002, 77(5): 413-421.
[10]
Vyas H, Ackerman MJ. Epinephrine QT stress testing in congenital long QT syndrome [J]. J Electrocardiol, 2006, 39(4 Suppl): S107-113.
[11]
Pflaumer A, Davis AM. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia [J]. Heart Lung Circ，2012, 21(2): 96-100.
[12]
Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia [J]. Circulation, 2001, 103: 196-200.
[13]
Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel [J]. Am J Hum Genet, 2001, 69(6): 1378-1384.
[14]
Viitasalo M, Oikarinen L, Vaananen H, Kontula K, Toivonen L, Swan H. U-waves and T-wave peak to T-wave end intervals in patients with catecholaminergic polymorphic ventricular tachycardia, effects of beta-blockers [J]. Heart Rhythm, 2008, 5(10): 1382-1388.
[15]
Gold MR, Bloomfield DM, Andersen KP, El-Sherif NE, Wilber DJ, Groh WJ. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification [J]. J Am Coll Cadiol, 2000, 36(7): 2247-2253.
[16]
Makarov L, Komoliatova V. Microvolt T-Wave Alternans during Holter Monitoring in Children and Adolescents [J]. Ann Noninvasive Electrocardiol, 2010,15(2):138-144.
[17]
Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients [J].Circulation, 1995, 91(5): 1512-1519.
[18]
Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, et al. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening [J]. Europace, 2010, 12(3): 417-423.
[19]
Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catechol-aminergic polymorphic ventricular tachycardia in mice and humans [J]. Nat Med, 2009, 15(4): 380-383.
[20]
Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, et al. Flecainide inhibits arrhythmogenic Ca(2+) waves by open state block of ryanodine receptor Ca(2+) release channels and reduction of Ca(2+) spark mass[J]. J Mol Cell Cardiol, 2010, 48(2): 293-301.
[21]
Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia [J]. J Am Coll Cardiol, 2011, 57(22): 2244-2254.
[22]
Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, et al. Inhibition of Cardiac Ca2+ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular Tachycardia [J]. Circ Arrhythm Electrophysiol, 2011, 4(2): 128-135.
[23]
Franquini JV, Medeiros AR, Andrade TU, Araujo MT, Moyses MR, Abreu GR, et al. Influence of renal denervation on blood pressure, sodium and water excretion in acute total obstructive apnea in rats [J]. Braz J Med Biol Res, 2009, 42(2): 214-219.
[24]
Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiaganglionect0my in the treatment of hypertension [J]．Ann Surg, 1941, 114(4): 753-775.
[25]
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A muhicentre safety and proof-of-principle cohort study[J]. Lancet, 2009, 373(9671): 1275-1281.
[26]
Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension [J]. N Engl J Med, 2009, 361(9): 932-934.
[27]
Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience [J]. Clin Res Cardiol, 2012, 101(1): 63-67.
